| 1 |
33782049 | Randomized Controlled Trial of the Gastrin/CCK2 Receptor Antagonist Netazepide in Patients with Barrett's Esophagus. | 2021 Jun |
2 |
| 2 |
27704617 | Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. | 2017 Mar |
2 |
| 3 |
27796466 | Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity. | 2017 Feb |
4 |
| 4 |
25665655 | Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist. | 2015 May |
2 |
| 5 |
24279703 | The regulation of gastric acid secretion - clinical perspectives. | 2014 Feb |
1 |
| 6 |
23179899 | The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression. | 2013 Jan |
2 |
| 7 |
23432415 | Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects. | 2013 Nov |
2 |
| 8 |
23432534 | Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects. | 2013 Nov |
5 |
| 9 |
24098507 | Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. | 2013 |
4 |
| 10 |
22607579 | Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. | 2012 Jul |
2 |
| 11 |
23072686 | Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. | 2012 Dec |
1 |
| 12 |
9042983 | YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. | 1997 Feb |
1 |